XTNT

SEC source: 0001902610-26-000002 · primary_doc.xml · nonDerivative · entry 2

Neils Scott C · CIK 0001902610 · CFO and Assistant Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,215,226

F3 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F3 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 869,878 shares issuable upon vesting and settlement of restricted stock unit awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001902610-26-000002 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · CFO and Assistant Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,243,381

F1 · shares: These shares will vest with respect to 100,000 shares on each of August 15, 2027, August 15, 2028, August 15, 2029, and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 869,878 shares issuable upon vesting and settlement of restricted stock unit awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001509284-26-000001 · primary_doc.xml · nonDerivative · entry 1

Lipschultz Tyler · CIK 0001509284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,745

F1 · shares: These shares are subject to a restricted stock unit (RSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 373,745 shares issuable upon vesting of RSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001183553-26-000001 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,129,633

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001975134-26-000001 · primary_doc.xml · nonDerivative · entry 1

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 733,136

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 681,087 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001981291-26-000003 · primary_doc.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,745

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 373,745 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001559834-26-000001 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,838,845

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on August 15, 2027, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 1,843,491 shares issuable upon settlement of DSUs granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

SEC source: 0001960742-26-000002 · primary_doc.xml · nonDerivative · entry 2

Schallenberger Mark A. · CIK 0001960742 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,106,087

F3 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F3 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 944,758 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001960742-26-000002 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,113,157

F1 · shares: These shares will vest with respect to 112,500 shares on each of August 15, 2027, August 15, 2028, August 15, 2029, and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 944,758 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001790461-26-000001 · primary_doc.xml · nonDerivative · entry 2

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,114,669

F3 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F3 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 1,720,123 shares issuable upon vesting and settlement of restricted stock unit awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001790461-26-000001 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,125,274

F1 · shares: These shares will vest with respect to 137,500 shares on each of August 15, 2027, August 15, 2028, August 15, 2029 and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 1,720,123 shares issuable upon vesting and settlement of restricted stock unit awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001960742-26-000001 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 663,157

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 523,794 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001902610-26-000001 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · CFO and Assistant Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 843,381

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 498,914 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 62,974 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001902610-25-000005 · primary_doc.xml · derivative · entry 2

Neils Scott C · CIK 0001902610 · CFO and Assistant Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 526,582

Underlying: Common Stock · 526,582 shares

Expires 2028-11-15

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (263,291).

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · derivative.underlying_shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (263,291).

F4 · balance_after: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (263,291).

SEC source: 0001902610-25-000005 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · CFO and Assistant Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 851,465

F1 · shares: These shares will vest with respect to 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and with respect to 65,825 shares on November 5, 2029 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 498,914 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 85,220 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001183553-25-000006 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 914,116

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

F3 · balance_after: The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5.

SEC source: 0001559834-25-000006 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515,570

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 1,520,215 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001975134-25-000003 · primary_doc.xml · nonDerivative · entry 1

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 517,619

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 465,570 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001183553-25-000005 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,228

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001509284-25-000004 · primary_doc.xml · nonDerivative · entry 1

Lipschultz Tyler · CIK 0001509284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,228

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 158,228 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001981291-25-000007 · primary_doc.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,228

F1 · shares: These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 158,228 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

SEC source: 0001790461-25-000003 · primary_doc.xml · derivative · entry 2

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 789,874

Underlying: Common Stock · 789,874 shares

Expires 2028-11-15

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (394,937).

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · derivative.underlying_shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (394,937).

F4 · balance_after: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (394,937).

SEC source: 0001790461-25-000003 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,575,274

F1 · shares: These shares will vest with respect to 98,734 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and with respect to 98,735 shares on November 5, 2029 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 1,213,677 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001960742-25-000003 · primary_doc.xml · derivative · entry 2

Schallenberger Mark A. · CIK 0001960742 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 584,506

Underlying: Common Stock · 584,506 shares

Expires 2028-11-15

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (292,253).

F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

F4 · derivative.underlying_shares: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (292,253).

F4 · balance_after: Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (292,253).

SEC source: 0001960742-25-000003 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 670,866

F1 · shares: These shares will vest with respect to 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and with respect to 73,064 shares on November 5, 2029 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes an aggregate of 523,794 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 44,500 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001902610-25-000003 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 588,174

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 235,623 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 85,220 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001902610-25-000004 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180,337

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 818,740 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0000947871-25-000392 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F2 · ownership.nature: These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-25-000392 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

Orbimed ROF II LLC · CIK 0001767936 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · ownership.nature: These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001235802-25-000006 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 622,305

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 264,659 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 167,726 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000087 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,190,942

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 862,294 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000065 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,291

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 264,659 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 189,972 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000066 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 943,736

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 274,584 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 245,568 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000071 · primary_doc.xml · nonDerivative · entry 2

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,961,773

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

F2 · balance_after: Includes 966,418 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000071 · primary_doc.xml · nonDerivative · entry 1

Vizirgianakis Stavros G. · CIK 0001559834 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,456,368

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting date.

F2 · balance_after: Includes 966,418 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000070 · primary_doc.xml · nonDerivative · entry 1

MITCHELL-KELLER LORI D · CIK 0001242852 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,124

F1 · shares: These shares are subject to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest and become issuable on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 162,162 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting dates.

SEC source: 0001235802-24-000069 · primary_doc.xml · nonDerivative · entry 1

McNamara Robert · CIK 0001387652 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 754,151

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 307,342 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000068 · primary_doc.xml · nonDerivative · entry 1

Beeson Jonn R. · CIK 0001975134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,391

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 307,342 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000067 · primary_doc.xml · nonDerivative · entry 1

BAKEWELL JOHN K · CIK 0001183553 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 755,888

F1 · shares: These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2025, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

F2 · balance_after: Includes 307,342 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000064 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,296,384

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes an aggregate of 862,294 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 433,024 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

SEC source: 0001235802-24-000027 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 664,423

F1 · shares: These shares will vest with respect to 44,388 shares on each of April 3, 2025, April 3, 2026, and April 3, 2027 and with respect to 44,387 shares on April 3, 2028 pursuant to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares, however, will occur at a later date pursuant to the terms of the award agreement.

F2 · balance_after: Includes an aggregate of 293,695 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 205,739 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001235802-24-000030 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,069

F1 · shares: These shares will vest and be issued with respect to 46,052 shares on each of April 3, 2025, April 3, 2026, and April 3, 2027 and with respect to 46,053 shares on April 3, 2028 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes an aggregate of 304,708 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 412,411 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001235802-24-000029 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,306,990

F1 · shares: These shares will vest and be issued with respect to 182,908 shares on each of April 3, 2025, April 3, 2026, April 3, 2027 and April 3, 2028 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes an aggregate of 905,848 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 433,0024 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001235802-24-000028 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 382,695

F1 · shares: These shares will vest and be issued with respect to 44,388 shares on each of April 3, 2025, April 3, 2026, and April 3, 2027 and with respect to 44,387 shares on April 3, 2028 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.

F2 · balance_after: Includes an aggregate of 293,695 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 66,750 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001235802-25-000007 · primary_doc.xml · nonDerivative · entry 1

Schallenberger Mark A. · CIK 0001960742 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,613

F1 · shares: The purpose of this Form 4 amendment (this "Form 4/A") is to adjust the number of shares issuable upon vesting and settlement of a deferred stock unit award granted on April 3, 2024. In addition, the adjustment has been made to the reporting person's vesting schedule in footnote (2) and the outstanding equity awards, including the number of deferred stock units as reflected on this Form 4/A and described in footnote (3) to this Form 4/A.

F2 · shares: These shares will vest and be issued with respect to 43,367 shares on each of April 3, 2025, April 3, 2026, and April 3, 2027 and with respect to 43,368 shares on April 3, 2028 pursuant to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares, however, will occur at a later date pursuant to the terms of the award agreement.

F3 · balance_after: Includes an aggregate of 289,613 shares issuable upon vesting and settlement of restricted stock unit awards or deferred stock unit awards granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 66,750 shares issuable upon vesting and settlement of restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

SEC source: 0001235802-24-000013 · primary_doc.xml · nonDerivative · entry 1

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 486,872

F1 · kind: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes 116,144 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 205,739 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000112 · primary_doc.xml · nonDerivative · entry 1

Brandt Kevin D · CIK 0001692661 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 815,860

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.228, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · balance_after: Includes 120,499 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 412,411 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000109 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,569,079

F1 · balance_after: Includes 174,216 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 433,024 shares to be issued upon vesting pursuant to restricted stock awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended from time to time, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-24-000016 · primary_doc.xml · nonDerivative · entry 1

Browne Sean E · CIK 0001790461 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,575,358

F1 · kind: The purpose of this Form 4 amendment is to correct the number of shares withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F1 · shares: The purpose of this Form 4 amendment is to correct the number of shares withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

F2 · balance_after: Includes 174,216 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan and 433,024 shares to be issued upon vesting pursuant to restricted stock awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended from time to time, all conditioned upon the Reporting Person remaining an employee of Xtant through the vesting dates.

SEC source: 0001235802-23-000097 · primary_doc.xml · derivative · entry 3

Neils Scott C · CIK 0001902610 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,501

Underlying: Common Stock · 135,501 shares

Expires 2033-08-15

F3 · derivative.exercise_date: This option vests with respect to 33,875 shares on August 15, 2024 and with respect to the remaining 75% of such shares over the three-year period thereafter in 12 as nearly equal as possible quarterly installments, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date.